FGF23 and X-linked hypophosphatemia: Untangling a potential direct pathogenic role for FGF23 is relevant for patients with XLH, as the current therapies for this rare disease include phosphate and activated vitamin D supplementation, which are associated with increases in FGF23 in both adults and children (28) and worsening enthesopathy in mice (29).